Affiliation:
1. Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-055 Katowice, Poland
Abstract
Diabetes is one of the leading chronic conditions worldwide, and breast cancer is the most prevalent cancer in women worldwide. The linkage between diabetes and its ability to increase the risk of breast cancer should always be analyzed in patients. This review focuses on the impact of antihyperglycemic therapy in breast cancer patients. Patients with diabetes have a higher risk of developing cancer than the general population. Moreover, diabetes patients have a higher incidence and mortality of breast cancer. In this review, we describe the influence of antidiabetic drugs from insulin and metformin to the current and emerging therapies, incretins and SGLT-2 inhibitors, on breast cancer prognosis. We also emphasize the role of obesity and the metastasis process in breast cancer patients who are treated with antidiabetic drugs.
Funder
Medical University of Silesia
Reference88 articles.
1. US Department of Health and Human Services (2020). National Diabetes Statistics Report, 2020. Natl. Diabetes Stat. Rep., 2, 987–999.
2. International Diabetes Federation (2015). IDF Diabetes Atlas, International Diabetes Federation. [6th ed.].
3. Ballotari, P., Vicentini, M., Manicardi, V., Gallo, M., Chiatamone Ranieri, S., Greci, M., and Giorgi Rossi, P. (2017). Diabetes and risk of cancer incidence: Results from a population-based cohort study in northern Italy. BMC Cancer, 17.
4. American Diabetes Association (2020). 6. Glycemic Targets: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S66–S76.
5. Diabetes and cancer: A consensus report;Giovannucci;Diabetes Care,2010